文献速递神经免疫认知障碍与痴呆

加拿大四省抗肿瘤坏死因子α使用者中多发性硬化症的风险:一项基于人群的研究

Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor α in 4 Canadian Provinces: A Population-Based Study.
PubMed 文献 · Neurology · 2022-10-28

该研究采用巢式病例对照设计,利用加拿大四省2000年1月至2018年3月的医疗数据库,比较抗TNFα使用者与非使用者在风湿病或炎症性肠病患者中的多发性硬化症风险。风湿病患者中抗TNFα暴露与MS风险升高相关(汇总校正IRR 2.05,95%CI 1.13-3.72),炎症性肠病患者中风险未达统计学显著(汇总校正IRR 1.35,95%CI 0.70-2.59)。

要点

  • 风湿病患者中,抗TNFα暴露者MS风险较非暴露者升高(汇总校正IRR 2.05,95%CI 1.13-3.72)。
  • 炎症性肠病患者中,抗TNFα暴露与MS风险的关联未达统计学显著(汇总校正IRR 1.35,95%CI 0.70-2.59)。
  • 作者认为这些发现可帮助临床医生和风湿病患者做出更知情的治疗决策,并需进一步研究验证炎症性肠病患者的结果。

核心结论

  • 抗TNFα使用与非使用者相比与MS风险升高相关,尤其在风湿病患者中。
  • 这些发现可帮助临床医生和风湿病患者做出更知情的治疗决策。
  • 需进一步研究验证这些结果在炎症性肠病患者中的适用性。

研究设计与样本

  • 巢式病例对照研究,使用加拿大4个省份2000年1月至2018年3月的基于人群的医疗保健链接数据库。
  • 通过经验证的病例定义识别所有居住在参与省份的风湿病或炎症性肠病患者。
  • 根据出生年±3年、疾病病程和卫生管理机构(基于居住地区)为每例MS病例匹配最多5例对照。
  • 采用条件逻辑回归计算校正潜在混杂因素后的发病率比(IRR),并使用随机效应模型进行荟萃分析以提供跨省合并估计。

主要发现

  • 在296,918例风湿病患者中,462例MS病例(80.1%女性,平均[SD]年龄47.4[14.6]岁)与2,296例对照(59.5%女性,平均[SD]年龄47.4[14.5]岁)匹配;抗TNFα暴露见于18例MS病例和42例对照。
  • 风湿病患者中,校正匹配变量、性别和Charlson合并症指数后,汇总IRR为2.05(95%CI 1.13-3.72)。
  • 在84,458例炎症性肠病患者中,190例MS病例(69.5%女性,平均[SD]年龄44.3[12.3]岁)与943例对照(54.1%女性,平均[SD]年龄44.2[12.2]岁)匹配;抗TNFα暴露见于23例MS病例和98例对照。
  • 炎症性肠病患者中,汇总校正IRR为1.35(95%CI 0.70-2.59)。

关键数值与推荐

  • 风湿病患者中抗TNFα暴露者MS的汇总校正IRR为2.05(95%CI 1.13-3.72)。
  • 炎症性肠病患者中抗TNFα暴露者MS的汇总校正IRR为1.35(95%CI 0.70-2.59)。
  • 抗TNFα暴露定义为索引日期(MS发病)前2年内任何一次抗TNFα配药。

临床怎么用

  • 作者认为这些发现可帮助临床医生和风湿病患者做出更知情的治疗决策。
  • 作者指出需进一步研究验证这些结果在炎症性肠病患者中的适用性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Antitumor necrosis factor α (TNFα) agents are a class of biologic drugs used for the treatment of several immune-mediated conditions. An increased risk of multiple sclerosis (MS) with their use has been suggested, but studies have been limited. Relevant population-based epidemiologic data linking anti-TNFα to MS are scarce. The objective was to compare the risk of MS in anti-TNFα users with nonusers among patients with rheumatic disease (RD) or inflammatory bowel disease (IBD). METHODS: A nested case-control study was conducted. Population-based health care-linked databases from 4 Canadian provinces were used. All patients with RD or IBD residing within a participating province between January 2000 and March 2018 were identified by validated case definitions. Any anti-TNFα dispensation in the 2 years before the index date (MS onset) was identified. Incident onset MS cases were ascertained using a validated algorithm. Up to 5 controls were matched to each MS case based on birth year ±3 years, disease duration, and health authority (based on region of residence). Conditional logistic regressions were used to calculate the incidence rate ratio (IRR) after adjusting for potential confounders. A meta-analysis was conducted to provide pooled estimates across provinces using random-effects models. RESULTS: Among 296,918 patients with RD patients, 462 MS cases (80.1% female, mean [SD] age, 47.4 [14.6] years) were matched with 2,296 controls (59.5% female, mean [SD] age, 47.4 [14.5] years). Exposure to anti-TNFα occurred in 18 MS cases and 42 controls. After adjusting for matching variables, sex, and the Charlson Comorbidity Index, the pooled IRR was 2.05 (95% CI, 1.13-3.72). Among 84,458 patients with IBD, 190 MS cases (69.5% female, mean [SD] age, 44.3 [12.3] years) were matched with 943 controls (54.1% female, mean [SD] age, 44.2 [12.2] years). Exposure to anti-TNFα occurred in 23 MS cases and 98 controls. The pooled adjusted IRR was 1.35 (95% CI, 0.70-2.59). DISCUSSION: The use of anti-TNFα was associated with an increased risk of MS compared with nonusers, especially among patients with RD. These findings could help clinicians and patients with RD to make more informed treatment decisions. Further studies are needed to validate these results for patients with IBD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Li L, Aviña-Zubieta JA, Bernstein CN, et al. Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor α in 4 Canadian Provinces: A Population-Based Study. Neurology. 2022. PMID: 36307225. doi:10.1212/WNL.0000000000201472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。